V. Rybakova

The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry)

E. Nasonov, A. Avdeeva, V. Rybakova, 2021, Rheumatology Science and Practice.

Relationship of cytokine level dynamics with longterm results of early rheumatoid arthritis therapy

A. Avdeeva, V. Rybakova, D. Dibrov, 2022, Rheumatology Science and Practice.

The role of monitoring the level of matrix metalloproteinase 3 in patients with rheumatoid arthritis on anti-B-cell therapy

A. Avdeeva, E. Nasonov, V. Rybakova, 2022, Rheumatology Science and Practice.

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar

A. Avdeeva, E. Nasonov, V. Rybakova, 2022, Modern Rheumatology Journal.

[The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, "BIOCAD") in patients with rheumatoid arthritis].

E. Nasonov, A. Avdeeva, N. Chichasova, 2019, Terapevticheskii arkhiv.

Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis

E. Nasonov, A. Lila, A. Avdeeva, 2019, Rheumatology Science and Practice.

Indicators of rheumatoid arthritis disease activity. An association with a patient’s psychological status

E. V. Likhacheva, E. Nasonov, V. Rybakova, 2020, Modern Rheumatology Journal.